Department of Neurology, Musashino Red Cross Hospital, Tokyo, Japan.
J Neuroimmunol. 2013 Jun 15;259(1-2):92-5. doi: 10.1016/j.jneuroim.2013.03.004. Epub 2013 Apr 6.
Serum amyloid A (SAA) is known to promote the development of T helper 17 cells (Th17) and can be a critical mediator of disease pathogenesis. We analyzed SAA levels in 40 patients with multiple sclerosis (MS) and related disorders, and 10 with non-inflammatory neurological disease (NIND) as controls. We found that SAA levels were significantly increased in neuromyelitis optica (NMO) patients and relapsing and remitting MS (RRMS) patients showing atypical phenotype with spinal cord lesions and smaller T2 lesion volume in brain MRI, resembling NMO. Therefore, SAA levels can be associated with clinical phenotypes in MS and NMO.
血清淀粉样蛋白 A（SAA）已知可促进辅助性 T 细胞 17 型（Th17）的发展，并且可以作为疾病发病机制的关键介质。我们分析了 40 例多发性硬化症（MS）和相关疾病患者以及 10 例非炎症性神经疾病（NIND）患者的 SAA 水平。我们发现视神经脊髓炎（NMO）患者和具有脊髓病变和较小的 T2 病变体积的复发性和缓解性多发性硬化症（RRMS）患者的 SAA 水平显着升高脑 MRI 中类似于 NMO 的表现。因此，SAA 水平可能与 MS 和 NMO 中的临床表型相关。
